MALIGNANCY: Multiple Myeloma
CLINICAL TRIALS:
Study title Phase Status
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Multiple Myeloma, NHL, and AMLPhase 1Recruiting
AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid LeukemiaPhase 1Recruiting
Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple MyelomaPhase 1Recruiting
Study Evaluating AMG 424 in Subjects With Multiple MyelomaPhase 1Recruiting
A Phase 1 Study of AMG 701 in Subjects With Multiple MyelomaPhase 1Recruiting
A Study of Carfilzomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology CentersPhase 2Recruiting
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.Phase 3Active, not recruiting
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple MyelomaPhase 4Not yet recruiting
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Subjects With Relapsed & Refractory Multiple MyelomaPhase 3Active, not recruiting
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaPhase 3Not yet recruiting
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple MyelomaPhase 1Active, not recruiting
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in EuropeObservationalRecruiting